Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc (PRTA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 5.16 M | -606,995,000 | 135.02 M | 696.38 M | 639.28 M |
| 2022 | 62 K | -703,933,000 | 135.99 M | 758.04 M | 719.1 M |
| 2021 | 13 K | -566,768,000 | 143.32 M | 609.37 M | 584.81 M |
| 2020 | 15 K | -277,542,000 | 148.97 M | 332.98 M | 299.28 M |
| 2019 | 68 K | -352,784,000 | 146.35 M | 419.27 M | 378.38 M |